Artikel ; Online: Design, Synthesis and In Vitro Evaluation of Levodopa Stearic Acid Hydrazide Conjugate for the Management of Parkinson's DiseaseNovel Conjugate for Parkinson's Disease.
2024 Band 74, Heft 2, Seite(n) 60–66
Abstract: Parkinson's disease is the highest prevalent neurodegenerative disease in elderly individuals after Alzheimer's disease. The pathological identification for Parkinson's disease is loss of dopaminergic neurons in substantia nigra region of the brain that ... ...
Abstract | Parkinson's disease is the highest prevalent neurodegenerative disease in elderly individuals after Alzheimer's disease. The pathological identification for Parkinson's disease is loss of dopaminergic neurons in substantia nigra region of the brain that in turn leads to dopamine deficiency that affects the body's normal physiological and neurological disorder. The important drawback in the modality of treatment is levodopa is only supplying depleted dopamine in the brain, it does not affect neurodegeneration. Even though levodopa manages the disease, an alternative treatment strategy is required to stop or prevent further degeneration of neuron. The compound with neuroprotector activity suits the requirement. Of them, stearic acid plays a vital role in protecting neurons against oxidative stress through a Phosphoinositide 3-kinase-dependent mechanism. Hence, our present study aimed to design, synthesize, and characterize the levodopa stearic acid hydrazide conjugate. Additionally, evaluate the cytotoxicity of synthesized compound in SHSY5Y: cell lines. In brief, levodopa was conjugated to the stearic acid successfully and was confirmed with Fourier-transform infrared spectroscopy, Nuclear magnetic resonance, and Mass Spectroscopy. |
---|---|
Mesh-Begriff(e) | Humans ; Aged ; Parkinson Disease/drug therapy ; Parkinson Disease/pathology ; Levodopa/pharmacology ; Levodopa/metabolism ; Dopamine/metabolism ; Neurodegenerative Diseases ; Phosphatidylinositol 3-Kinases/metabolism ; Dopaminergic Neurons ; Antiparkinson Agents/pharmacology ; Antiparkinson Agents/therapeutic use ; Antiparkinson Agents/metabolism ; Stearic Acids |
Chemische Substanzen | Levodopa (46627O600J) ; stearic acid (4ELV7Z65AP) ; Dopamine (VTD58H1Z2X) ; Phosphatidylinositol 3-Kinases (EC 2.7.1.-) ; Antiparkinson Agents ; Stearic Acids |
Sprache | Englisch |
Erscheinungsdatum | 2024-01-29 |
Erscheinungsland | Germany |
Dokumenttyp | Journal Article |
ZDB-ID | 2703847-6 |
ISSN | 2194-9387 ; 2194-9379 |
ISSN (online) | 2194-9387 |
ISSN | 2194-9379 |
DOI | 10.1055/a-2234-9859 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Uf I Zs.151: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.